NICE proposes to withdraw Alzheimer's drugs from NHS
BMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7490.495-a (Published 03 March 2005) Cite this as: BMJ 2005;330:495
This article has a correction. Please see:
- Zosia Kmietowicz
- London
The drugs donepezil, rivastigmine, galantamine, and memantine should no longer be prescribed on the NHS to treat Alzheimer's disease, says new draft guidance from the National Institute for Clinical Excellence (NICE).
NICE, the NHS prescribing watchdog for England and Wales, has retracted its previous guidance“issued in 2001 and which said that these drugs should be prescribed for Alzheimer's disease—after reviewing the latest evidence on efficacy and cost effectiveness. Patients currently receiving any of the drugs, however, can continue to do so. Memantine will be available only as part of …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.